by Pete Celano | Jun 14, 2025 | Uncategorized
Here’s a breakdown of the nine (9) late‑stage MASH (metabolic dysfunction‑associated steatohepatitis) candidates from BioSpace’s article, summarized by each medication: 🔹 1. Survodutide (Boehringer Ingelheim) A dual GLP‑1/GIP receptor agonist currently in Phase III...
by Pete Celano | Jun 12, 2025 | Uncategorized
Honoring one the great original innovators in Hepatology: Dame Sheila Patricia Violet Sherlock (1918–2001) was a pioneering British physician widely regarded as the founder of modern hepatology—the study of liver diseases. Her career transformed liver medicine through...
by Pete Celano | Jun 1, 2025 | Uncategorized
From the superb writer Wayne Eskridge of the Fatty Liver Foundation:”When we look at the success of modern medicine and track the change in death rate for major diseases over time, a tragedy becomes clear. Since 1970, medicine has slowly been winning against...
by Pete Celano | May 28, 2025 | Uncategorized
Decompensated Cirrhosis? Some $48K per year for the average patient.Compensated Cirrhosis ? Some $36K per year for the average patient.These are numbers from 2020 (add about 4% per year in cost inflation since then, on average), from a Medicare Advantage population. A...
by Pete Celano | May 26, 2025 | Uncategorized
The article titled “Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis” explores the emerging role of SGLT2 inhibitors beyond their established use in managing type 2 diabetes mellitus (T2DM). It...
